FingerMotion (NASDAQ:FNGR) reported $4.86 million in sales this quarter.
Agile Therapeutics Says Expects Q2 Twirla Demand To Be 21,000-21,500 Cycles
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range
Operating Expenses (OPEX) Expected to be Below Guided Range
PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) --
